Oppenheimer analyst Jeff Jones lowered the firm’s price target on Pharming (PHAR) to $30 from $31 and keeps an Outperform rating on the shares following quarterly results and business update. The firm notes Q3 revenues increased 12% quarter-over-quarter to $74.8M vs. its/consensus estimates of $78M/$77M, respectively, essentially flat, +1%, with Q2’s $74.1M. Management reiterated revenue 2024 guidance of $280M-$295M.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAR: